WO2016062266A1 - 氨氯地平在制备抑制癌症的医药组合物中的用途 - Google Patents
氨氯地平在制备抑制癌症的医药组合物中的用途 Download PDFInfo
- Publication number
- WO2016062266A1 WO2016062266A1 PCT/CN2015/092632 CN2015092632W WO2016062266A1 WO 2016062266 A1 WO2016062266 A1 WO 2016062266A1 CN 2015092632 W CN2015092632 W CN 2015092632W WO 2016062266 A1 WO2016062266 A1 WO 2016062266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- amlodipine
- 10min
- use according
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 96
- 201000011510 cancer Diseases 0.000 title claims abstract description 84
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract 4
- 230000002401 inhibitory effect Effects 0.000 title claims description 21
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 8
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 8
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 8
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 7
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 7
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 7
- 206010062129 Tongue neoplasm Diseases 0.000 claims abstract description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 7
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 7
- 201000007270 liver cancer Diseases 0.000 claims abstract description 7
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 7
- 201000005202 lung cancer Diseases 0.000 claims abstract description 7
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 7
- 201000006134 tongue cancer Diseases 0.000 claims abstract description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 7
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 230000002124 endocrine Effects 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 210000000683 abdominal cavity Anatomy 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 210000000038 chest Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract description 5
- 206010038389 Renal cancer Diseases 0.000 abstract description 5
- 201000010982 kidney cancer Diseases 0.000 abstract description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 89
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 58
- 238000012360 testing method Methods 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000002628 peritoneum cancer Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 229960004005 amlodipine besylate Drugs 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000003281 pleural cavity Anatomy 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to the use of new indications for amlodipine drugs, in particular the use of amlodipine drugs for inhibiting a variety of cancers.
- Amlodipine (Amlodipine or Amlodipine besylate, pulsed ingot (Norvasc, Pfizer brand name) and other generic drugs, can be with besylate, mesylate or maleic acid, etc. It is a "long-acting calcium channel blocker (CCB)" as an antihypertensive drug and a dihydropyridine (DHP) class for the treatment of angina pectoris.
- Amlodipine is a "dihydropyridine calcium antagonist” (calcium antagonist, or slow channel blocker) whose mechanism is to inhibit the movement of "calcium ions" into vascular smooth muscle cells and cardiac muscle cells. .
- amlodipine belongs to a kind of "peripheral arterial vasodilator" which acts directly on vascular smooth muscle, which reduces peripheral vascular resistance and lowers blood pressure.
- Amlodipine is used to treat high blood pressure and coronary heart disease.
- Amlodipine is a drug that has long been approved by the FDA and has a large number of drug transfer and human research results.
- amlodipine has the potential to inhibit cancer cells.
- cancer has long been the leading cause of death worldwide, and the number of cancer patients has increased year by year. Therefore, treating cancer has become an important issue.
- cancer drug treatment whether it is chemotherapy or target treatment, is intended to prevent cancer cells from replicating and dividing to block the spread and spread of tumors. According to statistics, only about five per million new drugs can enter the first Phase clinical trials. Further, many cancer cells successively develop drug resistance, which greatly reduces the effectiveness of drug use, and ultimately leads to failure of cancer treatment. This shows that drug development has a certain degree of difficulty.
- the present invention aims at the development of new indications for amlodipine drugs, and achieves the goal of new use of old drugs.
- amlodipine drugs have no or only minimal toxicity to normal cells, but amlodipine has a selective effect between tumor cells.
- the present invention provides a use of the amlodipine drug for the preparation of a pharmaceutical composition for inhibiting cancer, wherein the pharmaceutical composition comprises amlodipine besylate and a pharmaceutically acceptable salt.
- the cancer is selected from one or more of a chest-related cancer, an abdominal cavity-related cancer, an endocrine-related cancer, and a digestive tract-related cancer.
- the cancer is selected from the group consisting of an osteosarcoma-related cancer and a skin cancer-related cancer.
- chest cavity related cancer refers to lung cancer
- the abdominal cavity-related cancer is selected from the group consisting of bladder cancer or/and kidney cancer or/and cervical cancer.
- the endocrine-related cancer is selected from one or more of prostate cancer, breast cancer, and ovarian cancer.
- the digestive tract-related cancer is selected from one or more of the group consisting of gastric cancer, liver cancer, colon cancer, pancreatic cancer, and tongue cancer.
- the effective concentration of the amlodipine drug is from 20 mg/kg to 500 mg/kg per day.
- Figure 1 shows the use of the amlodipine of the present invention for inhibiting cancer cell analysis results
- FIG. 1 shows the effect of amlodipine on tumor volume
- Figure 3 shows the inhibitory effect of high-dose and low-dose amlodipine tumor growth
- Subculture of cell lines of different cancer types including cancerous lung cancer, gastric cancer, liver cancer, rectal cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, blood cancer, pancreatic cancer, ovarian cancer, tongue cancer Osteosarcoma, kidney cancer, and the control group also used normal cells of the kidney (HEK293 (Kidney)), fibroblast HFW (fibroblast), and lung epithelial cell BEAS-2B (Lung Epithelial) for testing.
- HEK293 Kidney
- fibroblast HFW fibroblast
- BEAS-2B Long Epithelial
- the cells corresponding to different species should be counted with the corresponding culture solution (Table 1), and the number of cells should be counted, and 2 ⁇ 10 6 cells should be returned. Then, the culture medium in which the cell strain was cultured was added to a volume of 10 ml, and the culture was continued for 2-3 days. The cells were then counted and dispensed into 96-well plates where the number of cells per well was fixed at 3000 and the volume was 100 ul.
- IC50 is the semi-inhibitory concentration (or semi-inhibition rate). It is a very important data in the indirect competition ELISA standard curve, and the standard curve is an S-shaped curve.
- the OD value of the control group without drug addition was B0
- the OD value of the experimental group to which the drug was added was B
- B/B0% was called the binding rate
- the concentration of the drug at the binding rate was 50%. It is called IC50.
- the smaller the value of IC50 the stronger the inhibitory effect of the drug.
- the original culture solution in the 96-well plate was aspirated, and a commercially available drug having a concentration of 10 ⁇ m and a volume of 100 ul was added to each well. After 72 hours, 100 ul of diluted WST-1 reagent was added to each well, and the dilution ratio was the culture solution and The volume ratio of the WST-1 stock solution was 9:1, and finally the total volume of each well plate was 200 ul. Then the 96-well plate was placed at 37 ° C for 30-90 minutes, using an elisa reader (ELISA) on the OD450. The absorbance values were detected and the survival rate of each cancer cell line was calculated.
- ELISA elisa reader
- the analysis of the inhibitory effect of amlodipine on pleural cavity-related cancer cells was mainly tested on two kinds of lung cancer cells.
- the cancer cell lines were A549 and H1650, respectively, and the results of cancer cell inhibition experiments were performed 4 times each, and the calculation was performed.
- the average value is shown in Table 2.
- the analysis of the inhibitory effect of amlodipine on peritoneal cancer-related cancer cells was mainly tested on two kinds of cells related to abdominal cancer-related cancer cells.
- the bladder cancer cell lines were TSGH and T24, respectively (Table 3), cervical cancer cell lines. They were HeLa cell line and C-33A cell line (Table 4), and the kidney cancer cell line was 786-O (Table 5).
- the results of cancer cell inhibition experiments were performed 4 times each, and the average value was calculated. The results are shown in Table 3. -5 is shown.
- prostate cancer cell lines were PC-3 and LNCap, respectively (Table 6), breast cancer cell lines.
- MCF7 and MDA-MB-231 were tested for cancer cell inhibition four times each, and the average value was calculated. The results are shown in Table 6-8.
- the gastric cancer cell lines were AGS and MKN-45, respectively (Table 9), liver cancer cell lines. They were HepG2 and Hep3B, respectively (Table 10), the colorectal cancer cell lines were HCT116-wt and LoVo cell lines (Table 11), and the pancreatic cancer cell lines were AsPC and BxPC cell lines, respectively (Table 12).
- the tongue cancer cell line was a SAS cell strain (Table 13), and the results of the cancer cell inhibition experiments were performed four times each, and the average value was calculated. The results are shown in Table 9-13.
- the osteosarctic cancer cell line is U2OS cell line (Table 14)
- the skin cancer cell lines are A375 and BCC cell lines (Table 15), each of which is done 4 times.
- the cancer cells inhibited the experimental results and the average values were calculated. The results are shown in Tables 14-15.
- the normal kidney cell line was HEK293 cell line (Table 16)
- the normal fibroblast cell line was HFW cell line (Table 17)
- the normal lung epithelial cell line was The BEAS-2B cell line (Table 18) was subjected to four times of cancer cell inhibition test results, and the average value was calculated. The results are shown in Table 16-18.
- mice Female BALB/cAnN.Cg-Foxn1nu/CrlNarl mice were used as samples (purchased from National Laboratory Animal Center), weighing 21 ⁇ 1g, subcutaneously injected into gastric cancer cells (AGS) and randomly divided into cages.
- the test drugs were divided into three groups: Normal control group, low dose (100 mg/kg/day), high dose (200 mg/kg/day).
- the tumor formed more than 100 mm3, the drug was administered by intraperitoneal injection every day; the tumor size was measured twice a week, and the tumor volume measurement formula was as follows: (L ⁇ W2); L represents the longest diameter of the tumor; W represents the shortest diameter of the tumor.
- the low dose and the high dose of ammonia chloride have a good inhibitory effect on the tumor, and the weight of the mice in each group did not decrease significantly during the experiment, thus indicating amlodipine regardless of Both high and low doses can make the tested mice have good health without death during the treatment.
- high and low doses of amlodipine can effectively reduce tumor volume growth and simultaneously reduce tumor volume, wherein high dose of amlodipine has a better effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
本发明提供了氨氯地平在制备治疗癌症的医药组合物中的用途,所述癌症包括肺癌、膀胱癌、肾脏癌、子宫颈癌、前列腺癌、乳癌、卵巢癌、胃癌、肝癌、大肠癌、胰脏癌、舌癌等。
Description
本发明涉及氨氯地平药物的新适应症的应用,尤其所述氨氯地平药物具有抑制多种癌症的用途。
氨氯地平(Amlodipine或Amlodipine besylate、脉优锭(Norvasc、辉瑞公司商标名)及其它学名药、可与苯磺酸(besylate)、甲磺酸酯(mesylate)或马来酸(maleic acid)等制备成复方药)是一种作为抗高血压药和治疗心绞痛的二氢吡啶(DHP)类的"长效钙通道阻滞药(CCB)"。氨氯地平是一种"二氢吡啶类钙拮抗剂"(钙离子拮抗剂、或慢通道阻滞剂),其机制为抑制"钙离子"移动到血管平滑肌细胞和心肌细胞(cardiac muscle cell)。因此,氨氯地平是属于一种"外周动脉血管扩张剂"(peripheral arterial vasodilator)会直接作用于血管平滑肌上,使外周血管阻力减少进而血压降低。氨氯地平是用来治疗高血压及冠状动脉性心脏病。氨氯地平是早已被FDA所认可的用药,具有大量药物机转及人体研究成果资料。
由于临床应用上的明显差异,因此从来没有人认为氨氯地平具有抑制癌症细胞的可能性。
癌症长期高居全球死因之首,且罹患癌症人数更是逐年攀升,因此治疗癌症俨然成为重要的课题。一般来说,癌症药物治疗无论是化学治疗或标靶治疗,目的多是让癌细胞无法复制、分裂,来阻断肿瘤的蔓延扩张。根据统计,平均每一万个新药约只有五个能够进入第一
期临床试验。进一步,许多癌细胞相继产生抗药性,使药物的使用成效大幅降低,最终导致癌症治疗失败。由此可见药物开发具有一定的困难程度。
因此,如何能让癌症药物的快速的可以被开发出来,并且尽可能的减少临床失败的机率,在癌症病学上是一个非常急迫又重要的课题。
发明内容
为解决上述的问题,本发明针对氨氯地平药物进行新适应症的研发,而达到老药新用的目标。
经过实验设计结果显示氨氯地平药物对正常细胞没有或仅有微小的毒性,但氨氯地平在肿瘤细胞之间具有选择性的影响。
本发明提供一种制备氨氯地平药物在制备抑制癌症的医药组合物中的用途,其中所述医药组合物包含氨氯地平药物(Amlodipine besylate)及药学上可接受的盐类所组成。
本发明一实施例中,其中所述癌症选自胸腔相关癌症、腹腔相关癌症、内分泌相关癌症、消化道相关癌症中的一种或多种。
本发明一实施例中,其中所述癌症选自骨肉瘤相关癌症、皮肤癌相关癌症。
本发明一实施例中,其中所述胸腔相关癌症指的是肺癌。
本发明一实施例中,其中所述腹腔相关癌症选自膀胱癌或/和肾脏癌或/和子宫颈癌。
本发明一实施例中,其中所述内分泌相关癌症选自前列腺癌、乳癌、卵巢癌中的一种或多种。
本发明一实施例中,其中所述消化道相关癌症选自胃癌、肝癌、大肠癌、胰脏癌及舌癌中的一种或多种。
本发明一实施例中,其中所述氨氯地平药物的有效剂量浓度为每日20mg/kg~500mg/kg。
图1显示本发明氨氯地平用药应用于抑制癌细胞分析结果
图2显示氨氯地平用药可对肿瘤体积的效果
图3显示高剂量及低剂量氨氯地平肿瘤生长的抑制效果
各种癌症细胞株建立
将不同癌症类型的细胞株进行继代培养,癌症细胞种类包含肺癌、胃癌、肝癌、直肠癌、皮肤癌、子宫颈癌、前列腺癌、膀胱癌、乳癌、血癌、胰腺癌、卵巢癌、舌癌、骨肉瘤、肾脏癌,并且对照组亦使用肾脏(HEK293(Kidney))、纤维母细胞HFW(fibroblast)、肺部上皮细胞BEAS-2B(Lung Epithelial)的正常细胞做测试。(表一)
先将各细胞于培养液培养后,由于各细胞的属性不同,因此针对不同种的细胞也要用相对应的培养液(表一),计算细胞数目,回种2×106个细胞数,然后加入培养该细胞株的培养液补至体积为10ml,继续培养2-3天。之后将细胞计数,并分装至96孔盘,其中每孔的细胞数目固定为3000个,且体积为100ul。
IC50即半抑制浓度(或称半抑制率)。在间接竞争ELISA标准曲线中是一个非常重要的数据,标准曲线是一个S型曲线。ICELISA中,不添加药物的对照组的OD值定为B0,添加了药物的实验组的OD值为B,B/B0%就叫做结合率,在结合率为50%时所对应的药物的浓度就叫做IC50。一般IC50的数值越小表示药物的抑制效果越强。
表一、癌症测试细胞株及其培养所用的培养液
细胞存活分析方法
将96孔盘中原有的培养液吸掉,每孔加入浓度10um、体积100ul的市售药物,放置72小时后,每孔再加入100ul已稀释的WST-1试剂,该稀释比例为培养液与WST-1原液的体积比为9∶1,最后每个孔盘的总体积为200ul,然后将96孔盘放置于37℃,30~90分钟,利用elisa reader(酶联免疫检测仪)于OD450侦测吸光值,并计算各癌症细胞株的存活率。
氨氯地平药对于各种癌细胞分析结果
氨氯地平对胸腔相关癌症细胞抑制效果的测试
本分析氨氯地平对胸腔相关癌症细胞抑制效果的测试,主要针对两种肺癌细胞进行测试,癌细胞株分别为A549和H1650两个细胞株,各做4次的癌细胞抑制实验结果,并且计算其平均值,结果如表二所示。
表二、氨氯地平对肺癌相关癌症细胞抑制测试
0524-10min | 0526-10min | 0529-10min | 0531-10min | 平均 | |
A549 | 103.63 | 138.67 | 107.04 | 91.91 | 110.31 |
1-10min | 2-20min | 3-20min | 4-20min | 平均 | |
H1650 | 103.6 | 97.5 | 116.6 | 123.2 | 110.2 |
氨氯地平对腹腔相关癌症细胞抑制效果的测试
本分析氨氯地平对腹腔相关癌症细胞抑制效果的测试,主要针对两种腹腔相关癌症种类细胞进行测试,膀胱癌细胞株分别为TSGH和T24两个细胞株(表三),子宫颈癌细胞株分别为HeLa细胞株与C-33A细胞株(表四),肾脏癌细胞株为786-O(表五),各做4次的癌细胞抑制实验结果,并且计算其平均值,结果如表3-5所示。
表三、氨氯地平对膀胱癌相关癌症细胞抑制测试
0510-10min | 0512-10min | 0515-10min | 0517-10min | 平均 | |
TSGH | 34.41 | 35.42 | 35.90 | 39.26 | 36.2 |
1-30min | 2-20min | 3-20min | 4-20min | 平均 | |
T24 | 108.0 | 82.3 | 92.2 | 89.9 | 93.1 |
表四、氨氯地平对子宫颈癌相关癌症细胞抑制测试
0524-10min | 0526-10min | 0529-10min | 0531-10min | 平均 | |
HeLa | 93.70 | 103.69 | 97.06 | 110.70 | 101.29 |
1 | 2 | 3 | 4 | 平均 | |
C-33A | 32.7 | 33.1 | 32.7 | 36.4 | 33.7 |
表五、氨氯地平对肾脏癌相关癌症细胞抑制测试
1 | 2 | 3 | 4 | 平均 | |
786-O | 70.9 | 94.0 | 47.7 | 80.1 | 73.2 |
氨氯地平对内分泌相关癌症细胞抑制效果的测试
本分析氨氯地平对腹腔相关癌症细胞抑制效果的测试,主要针对三种内分泌相关癌症种类细胞进行测试,前列腺癌细胞株分别为PC-3和LNCap两个细胞株(表六),乳癌细胞株分别为MCF7和MDA-MB-231两个细胞株(表七),卵巢癌细胞株分别为
NIH-OVCAR-3细胞株和TOV-21G(表八),各做4次的癌细胞抑制实验结果,并且计算其平均值,结果如表6-8所示。
表六、氨氯地平对前列腺癌相关癌症细胞抑制测试
表七、氨氯地平对乳癌相关癌症细胞抑制测试
0612-10min | 0614-10min | 0616-10min | 0619-10min | 平均 | |
MCF7 | 73.83 | 82.90 | 76.46 | 88.76 | 80.49 |
0612-10min | 0614-10min | 0616-10min | 0619-10min | 平均 | |
MDA-MB-231 | 92.35 | 84.94 | 60.81 | 92.75 | 82.71 |
表八、氨氯地平对卵巢癌相关癌症细胞抑制测试
7-3-30min | 7-4-30min | 7-7-30min | 7-4-30min | 平均 | |
NIH-OVCAR-3 | 85.5 | 86.5 | 85.0 | 109.3 | 91.6 |
7-3-30min | 7-4-30min | 7-7-30min | 7-4-30min | 平均 | |
TOV-21G | 104.8 | 85.5 | 88.7 | 95.2 | 93.5 |
氨氯地平对消化道相关癌症细胞抑制效果的测试
分析氨氯地平对消化道相关癌症细胞抑制效果的测试,主要针对五种消化道相关癌症种类细胞进行测试,胃癌细胞株分别为AGS和MKN-45两个细胞株(表九),肝癌细胞株分别为HepG2和Hep3B两个细胞株(表十),大肠癌细胞株分别为HCT116-wt和LoVo细胞株(表十一),胰脏癌细胞株分别为AsPC和BxPC细胞株(表十二),舌癌细胞株为SAS细胞株(表十三),各做4次的癌细胞抑制实验结果,并且计算其平均值,结果如表9-13所示。
表九、氨氯地平对胃癌相关癌症细胞抑制测试
0510-10min | 0512-10min | 0515-10min | 0517-10min | 平均 | |
AGS | 11.50 | 11.42 | 12.94 | 12.88 | 12.2 |
0510-10min | 0512-10min | 0515-10min | 0517-10min | 平均 |
MKN-45 | 76.45 | 100.48 | 86.70 | 82.11 | 86.4 |
表十、氨氯地平对肝癌相关癌症细胞抑制测试
0524-20min | 0526-20min | 0529-20min | 0531-20min | 平均 | |
HepG2 | 90.26 | 92.51 | 104.32 | 92.94 | 95.01 |
0612-20min | 0614-20min | 0616-20min | 0619-20min | 平均 | |
Hep3B | 119.61 | 149.06 | 107.82 | 117.19 | 123.42 |
表十一、氨氯地平对大肠癌相关癌症细胞抑制测试
0602-30min | 0605-10min | 0607-10min | 0609-10min | 平均 | |
HCT116-wt | 80.65 | 96.84 | 76.17 | 59.35 | 78.26 |
0616-10min | 0619-10min | 0621-10min | 0623-10min | 平均 | |
LoVo | 84.12 | 76.35 | 100.28 | 81.51 | 85.56 |
表十二、氨氯地平对胰脏癌相关癌症细胞抑制测试
1-7-3-30min | 1-7-4-30min | 1-7-7-30min | 1-4-30min | 平均 | |
AsPC | 82.0 | 93.9 | 97.0 | 78.3 | 87.8 |
3-7-3-30min | 3-7-4-30min | 3-7-7-30min | 3-4-30min | 平均 | |
BxPC | 74.8 | 124.1 | 82.5 | 115.0 | 99.1 |
表十三、氨氯地平对舌癌相关癌症细胞抑制测试
6-26-10min | 6-28-10min | 6-30-10min | 7-3-10min | 平均 | |
SAS | 87.95 | 67.29 | 109.10 | 114.86 | 94.80 |
氨氯地平对其他癌症细胞抑制效果的测试
分析氨氯地平对其他类型癌正进行测试,骨肉癌细胞株为U2OS细胞株(表十四),皮肤癌细胞株分别为A375和BCC两个细胞株(表十五),各做4次的癌细胞抑制实验结果,并且计算其平均值,结果如表14-15所示。
表十四、氨氯地平对骨肉瘤相关癌症细胞抑制测试
6-26-10min | 6-28-10min | 6-30-10min | 7-3-10min | 平均 | |
U2OS | 61.80 | 65.44 | 67.75 | 89.25 | 71.06 |
表十五、氨氯地平对皮肤癌相关癌症细胞抑制测试
0602-30min | 0605-10min | 0607-10min | 0609-10min | 平均 | |
A375 | 96.57 | 138.30 | 143.16 | 168.64 | 136.67 |
0602-30min | 0605-10min | 0607-10min | 0609-10min | 平均 | |
BCC | 59.60 | 111.99 | 89.23 | 151.09 | 102.98 |
对照组实验设计
氨氯地平对正常细胞抑制效果的测试
分析氨氯地平对多种正常细胞进行测试,正常肾脏细胞株为HEK293细胞株(表十六),正常纤维母细胞细胞株为HFW细胞株(表十七),正常肺部上皮细胞细胞株为BEAS-2B细胞株(表十八),各做4次的癌细胞抑制实验结果,并且计算其平均值,结果如表16-18所示。
表十六、氨氯地平对正常肾脏细胞抑制测试
0602-30min | 0605-30min | 0607-30min | 0609-30min | 平均 | |
HEK293 | 87.83 | 106.24 | 96.85 | 96.93 | 96.96 |
表十七、氨氯地平对正常纤维母细胞抑制测试
0612-10min | 0614-10min | 0616-10min | 0619-10min | 平均 | |
HFW | 88.57 | 85.34 | 105.67 | 78.27 | 89.46 |
表十八、氨氯地平对正常肺部上皮细胞抑制测试
0510-10min | 0512-10min | 0515-10min | 0517-10min | 平均 | |
BEAS-2B | 80.87 | 87.51 | 88.48 | 59.33 | 79.05 |
针对氨氯地平对各种癌症细胞抑制效果汇整于表十九中,清楚看出氨氯地平对于多项癌症有明显的抑制效果。经过发明人实验结果,氨氯地平药物对于不同的癌症细胞有明显的抑制效果。(图一)
表十九、氨氯地平对各种癌症细胞抑制效果的汇整
癌症细胞 | 抑制效果 |
肺癌 | 110.28 |
膀胱癌 | 64.66 |
子宫颈癌 | 67.49 |
前列腺癌 | 73.20 |
乳癌 | 68.18 |
卵巢癌 | 81.60 |
胃癌 | 92.55 |
肝癌 | 49.31 |
大肠癌 | 109.21 |
胰脏癌 | 81.91 |
舌癌 | 93.47 |
骨肉癌 | 94.80 |
皮肤癌 | 71.06 |
正常细胞 | 抑制效果 |
肾脏 | 119.82 |
纤维母细胞 | 96.96 |
肺部上皮细胞 | 89.46 |
动物实验分析
本实验使用雌性BALB/cAnN.Cg-Foxn1nu/CrlNarl小鼠为样本(购自国家实验动物中心),体重为21±1g,皮下注射胃癌细胞(AGS)后随机分笼,测试药物分成三组:正常对照组、低剂量(100mg/kg/day)、高剂量(200mg/kg/day)。肿瘤形成超过100mm3后,每天采取腹腔注射方式给予药物;每周测量肿瘤大小两次,肿瘤体积测量公式如下:(L×W2);L代表肿瘤最长直径;W代表肿瘤最短直径。
表二十、氨氯地平于动物实验对癌症对癌症之抑制效果
依据第2图的结果,低剂量与高剂量的氨氯地平均对肿瘤具有良好的抑制效果,且于实验过程中各组小鼠的重量均未出现明显降低的现象,因此表示氨氯地平不论高低剂量在治疗过程均能使受测小鼠具有良好的健康状态而不死亡。
依据第3图的结果,高低剂量的氨氯地平可有效减缓肿瘤体积增长,并可同时减少肿瘤体积,其中以高剂量的氨氯地平具有较佳的效果。
上列详细说明是针对本发明之一可行实施例的具体说明,惟该实施例并非用以限制本发明的专利范围,凡未脱离本发明技艺精神所为的等效实施或变更,均应包含于本发明的专利范围中。
Claims (8)
- 一种氨氯地平药物在制备抑制癌症的医药组合物中的用途,其特征是,所述医药组合物包含氨氯地平药物及药学上可接受的盐类所组成。
- 如权利要求1所述的用途,其特征是,所述癌症是选自由胸腔相关癌症、腹腔相关癌症、内分泌相关癌症、消化道相关癌症中的一种或多种。
- 如权利要求1所述的用途,其特征是,所述癌症的选自由骨肉瘤相关癌症、皮肤癌相关癌症、血癌相关癌症中一种或多种。
- 如权利要求2所述的用途,其特征是,所述胸腔相关癌症为肺癌。
- 如权利要求2所述的用途,其特征是,所述腹腔相关癌症选自膀胱癌或/和子宫颈癌。
- 如权利要求2所述的用途,其特征是,所述内分泌相关癌症是选自由前列腺癌、乳癌、卵巢癌中的一种或多种。
- 如权利要求2所述的用途,其特征是,所述消化道相关癌症系选自由胃癌、肝癌、大肠癌、胰脏癌、舌癌中的一种或多种。
- 如权利要求1所述的用途,其特征是,所述有效剂量浓度为每日20mg/kg~500mg/kg。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462068298P | 2014-10-24 | 2014-10-24 | |
US62/068,298 | 2014-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016062266A1 true WO2016062266A1 (zh) | 2016-04-28 |
Family
ID=55760314
Family Applications (21)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/092666 WO2016062269A1 (zh) | 2014-10-24 | 2015-10-23 | 阿那格雷在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092761 WO2016062279A1 (zh) | 2014-10-24 | 2015-10-23 | 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途 |
PCT/CN2015/092686 WO2016062271A1 (zh) | 2014-10-24 | 2015-10-23 | 抗生素药物用于制备治疗癌症的医药组合物的用途 |
PCT/CN2015/092677 WO2016062270A1 (zh) | 2014-10-24 | 2015-10-23 | 呼吸系统疾病用药用于制备抗癌医药组合物的用途 |
PCT/CN2015/092632 WO2016062266A1 (zh) | 2014-10-24 | 2015-10-23 | 氨氯地平在制备抑制癌症的医药组合物中的用途 |
PCT/CN2015/092617 WO2016062265A1 (zh) | 2014-10-24 | 2015-10-23 | 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092776 WO2016062286A1 (zh) | 2014-10-24 | 2015-10-23 | 脱克钙药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092714 WO2016062275A1 (zh) | 2014-10-24 | 2015-10-23 | 阿折地平在制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092781 WO2016062290A1 (zh) | 2014-10-24 | 2015-10-23 | 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092768 WO2016062281A1 (zh) | 2014-10-24 | 2015-10-23 | 心血管疾病用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092779 WO2016062288A1 (zh) | 2014-10-24 | 2015-10-23 | 代谢性疾病药物用于制备抑制癌症的医药组合物的用途 |
PCT/CN2015/092771 WO2016062283A1 (zh) | 2014-10-24 | 2015-10-23 | 抗发炎用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092753 WO2016062278A1 (zh) | 2014-10-24 | 2015-10-23 | 内分泌疾病用药在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092782 WO2016062291A1 (zh) | 2014-10-24 | 2015-10-23 | 千忧解药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092777 WO2016062287A1 (zh) | 2014-10-24 | 2015-10-23 | 山喜多药物在用于制备抑制癌症的医药组合物中的用途 |
PCT/CN2015/092775 WO2016062285A1 (zh) | 2014-10-24 | 2015-10-23 | 神经系统疾病用药在制备抗癌医药组合物中的应用 |
PCT/CN2015/092746 WO2016062277A1 (zh) | 2014-10-24 | 2015-10-23 | 驱虫药用于制备抗癌医药组合物中的应用 |
PCT/CN2015/092702 WO2016062274A1 (zh) | 2014-10-24 | 2015-10-23 | 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092653 WO2016062267A1 (zh) | 2014-10-24 | 2015-10-23 | 奈必洛尔在制备抑制癌症的医药组合物中的用途 |
PCT/CN2015/092697 WO2016062272A1 (zh) | 2014-10-24 | 2015-10-23 | 免疫疾病用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092780 WO2016062289A1 (zh) | 2014-10-24 | 2015-10-23 | 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/092666 WO2016062269A1 (zh) | 2014-10-24 | 2015-10-23 | 阿那格雷在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092761 WO2016062279A1 (zh) | 2014-10-24 | 2015-10-23 | 苹果酸丙氯陪拉辛锭用于制备治疗癌症药物的用途 |
PCT/CN2015/092686 WO2016062271A1 (zh) | 2014-10-24 | 2015-10-23 | 抗生素药物用于制备治疗癌症的医药组合物的用途 |
PCT/CN2015/092677 WO2016062270A1 (zh) | 2014-10-24 | 2015-10-23 | 呼吸系统疾病用药用于制备抗癌医药组合物的用途 |
Family Applications After (16)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/092617 WO2016062265A1 (zh) | 2014-10-24 | 2015-10-23 | 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092776 WO2016062286A1 (zh) | 2014-10-24 | 2015-10-23 | 脱克钙药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092714 WO2016062275A1 (zh) | 2014-10-24 | 2015-10-23 | 阿折地平在制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092781 WO2016062290A1 (zh) | 2014-10-24 | 2015-10-23 | 氨苯蝶啶药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092768 WO2016062281A1 (zh) | 2014-10-24 | 2015-10-23 | 心血管疾病用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092779 WO2016062288A1 (zh) | 2014-10-24 | 2015-10-23 | 代谢性疾病药物用于制备抑制癌症的医药组合物的用途 |
PCT/CN2015/092771 WO2016062283A1 (zh) | 2014-10-24 | 2015-10-23 | 抗发炎用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092753 WO2016062278A1 (zh) | 2014-10-24 | 2015-10-23 | 内分泌疾病用药在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092782 WO2016062291A1 (zh) | 2014-10-24 | 2015-10-23 | 千忧解药物在用于制备治疗癌症的医药组合物中的用途 |
PCT/CN2015/092777 WO2016062287A1 (zh) | 2014-10-24 | 2015-10-23 | 山喜多药物在用于制备抑制癌症的医药组合物中的用途 |
PCT/CN2015/092775 WO2016062285A1 (zh) | 2014-10-24 | 2015-10-23 | 神经系统疾病用药在制备抗癌医药组合物中的应用 |
PCT/CN2015/092746 WO2016062277A1 (zh) | 2014-10-24 | 2015-10-23 | 驱虫药用于制备抗癌医药组合物中的应用 |
PCT/CN2015/092702 WO2016062274A1 (zh) | 2014-10-24 | 2015-10-23 | 消化系统疾病用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092653 WO2016062267A1 (zh) | 2014-10-24 | 2015-10-23 | 奈必洛尔在制备抑制癌症的医药组合物中的用途 |
PCT/CN2015/092697 WO2016062272A1 (zh) | 2014-10-24 | 2015-10-23 | 免疫疾病用药物在制备抑制癌症的医药组合物中的应用 |
PCT/CN2015/092780 WO2016062289A1 (zh) | 2014-10-24 | 2015-10-23 | 帕罗西汀药物用于制备治疗癌症的医药组合物中的用途 |
Country Status (9)
Country | Link |
---|---|
US (7) | US10098852B2 (zh) |
EP (3) | EP3222278B1 (zh) |
JP (1) | JP6539345B2 (zh) |
KR (1) | KR102490334B1 (zh) |
CN (3) | CN107106523A (zh) |
AU (2) | AU2015335391B2 (zh) |
ES (2) | ES2954860T3 (zh) |
TW (21) | TW201615197A (zh) |
WO (21) | WO2016062269A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019204764A1 (en) * | 2018-04-19 | 2019-10-24 | Washington University | Compositions and methods of use thereof for treatment of proteinopathies |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1993360T3 (pl) | 2005-12-28 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu |
WO2016062269A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 阿那格雷在用于制备治疗癌症的医药组合物中的用途 |
ES2761776T3 (es) | 2014-12-22 | 2020-05-21 | Suda Pharmaceuticals Ltd | Prevención y tratamiento de la enfermedad metastásica en pacientes con cáncer trombocitótico |
WO2017116049A1 (ko) * | 2015-12-31 | 2017-07-06 | 경북대학교 산학협력단 | 설폰아마이드계 화합물을 유효성분으로 포함하는 암의 치료 및 전이 억제용 약학적 조성물 |
EP3241562A1 (en) * | 2016-05-02 | 2017-11-08 | Fundació Institut Mar d'Investigacio Medica | Zonisamide for use in the treatment of breast cancer |
CN106074474A (zh) * | 2016-06-15 | 2016-11-09 | 中南大学湘雅医院 | 羟苄丝肼及其在药学上可接受的盐在制备抗肿瘤药物方面的应用 |
WO2018072135A1 (zh) | 2016-10-19 | 2018-04-26 | 微菌方舟生物科技股份有限公司 | 二氢吡啶类钙拮抗剂用于治疗癌症的用途 |
CN108066345A (zh) * | 2016-11-14 | 2018-05-25 | 武汉华杰世纪生物医药有限公司 | 一种具有抗肿瘤作用的化合物 |
EP3558276A1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
US20200179404A1 (en) * | 2017-06-09 | 2020-06-11 | Regents Of The University Of Minnesota | Skin care formulations and skin cancer treatment |
JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
WO2019008516A2 (en) * | 2017-07-03 | 2019-01-10 | Menri Group Ltd. | TREATMENT OF CANCER WITH DIHYDROPYRIDINES |
JP2019064976A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
KR101933805B1 (ko) | 2017-10-17 | 2018-12-28 | 성균관대학교산학협력단 | 옥셀라딘시트레이트를 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학적 조성물 |
CN108186652A (zh) * | 2017-12-28 | 2018-06-22 | 深圳大学 | 缝隙连接细胞间通迅抑制剂甘珀酸在制备预防和治疗肝细胞癌药物中的应用 |
BR112020015316A2 (pt) | 2018-01-30 | 2020-12-08 | Apnimed, Inc. (Delaware) | Métodos e composições para o tratamento da apneia do sono |
AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
FR3090084B1 (fr) | 2018-12-18 | 2023-10-13 | Securengy | Projectile pour armes à feu ou air comprimé pour emport liquide ou pulvérulent. |
US20220072089A1 (en) * | 2018-12-19 | 2022-03-10 | University Of Vermont And State Agricultural College | Cancer therapeutic compositions and methods |
CN113924090A (zh) * | 2019-04-04 | 2022-01-11 | 大邱庆北尖端医疗产业振兴财团 | 用于预防或治疗癌症的包含曲美布汀或其药学上可接受的盐作为活性成分的药物组合物 |
WO2020206078A1 (en) * | 2019-04-05 | 2020-10-08 | University Of North Texas Health Science Center At Fort Worth | Antidepressants for the treatment or prevention of memory loss and/or cognitive decline or dysfunction in aging |
US20220146492A1 (en) * | 2019-04-11 | 2022-05-12 | Ian Basil Shine | Cell membrane permeability restoring therapy |
CN110179803A (zh) * | 2019-05-31 | 2019-08-30 | 天津科技大学 | 一种噻吨溴类化合物的应用 |
CN110742890A (zh) * | 2019-10-24 | 2020-02-04 | 暨南大学 | 洛美利嗪在制备抗结肠癌药物中的应用 |
CN110876800B (zh) * | 2019-11-18 | 2023-06-27 | 中南大学 | 米卡芬净在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN110840887A (zh) * | 2019-11-18 | 2020-02-28 | 杭州彗搏科技有限公司 | 三氯苯达唑在制备治疗乳腺癌的药物中的应用 |
CN111067899B (zh) * | 2020-01-08 | 2021-03-05 | 温州医科大学 | 一种抗疟药物磷酸伯氨喹在制备治疗白血病药物上的应用 |
US11304969B2 (en) * | 2020-01-24 | 2022-04-19 | The Florida International Univeristy Board Of Trustees | Treatments of prostate cancer |
CN111973593A (zh) * | 2020-05-09 | 2020-11-24 | 深圳市罗湖区人民医院 | 硝唑尼特及其药学上可接受的盐在制备治疗膀胱癌药物中的用途 |
CN111557941A (zh) * | 2020-06-15 | 2020-08-21 | 浙江大学 | Plod2的小分子抑制剂米诺地尔在肿瘤治疗中的应用 |
CN111848717A (zh) * | 2020-08-07 | 2020-10-30 | 四川大学 | 靶向调控线粒体能量代谢的化合物及其应用和药物 |
TW202214244A (zh) * | 2020-08-10 | 2022-04-16 | 國立彰化師範大學 | 具有協同抗癌功效之氯硝柳胺(Niclosamide)和雙硫侖(Disulfiram)醫藥組合物及其用途 |
CN112274525B (zh) * | 2020-12-04 | 2022-04-08 | 遵义医科大学 | 一种化疗药物组合物及其应用 |
CN112336725A (zh) * | 2020-12-11 | 2021-02-09 | 吴照球 | 甲氧苄啶的医药新用途 |
CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN112569215A (zh) * | 2020-12-30 | 2021-03-30 | 东莞市人民医院 | 度米芬在制备防治结直肠癌的药物中的应用 |
EP4108244A1 (en) * | 2021-06-25 | 2022-12-28 | Universität Regensburg | Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies |
CN113663071B (zh) * | 2021-06-28 | 2022-12-30 | 四川大学 | Fbxl2激活剂在制备治疗egfr驱动的肺癌的药物中的用途 |
WO2023006954A1 (en) | 2021-07-30 | 2023-02-02 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Asenapine for use in cancer |
WO2023035200A1 (zh) * | 2021-09-09 | 2023-03-16 | 中国福利会国际和平妇幼保健院 | 五氟利多在制备治疗子宫内膜癌的药物中的应用 |
CN115887455B (zh) * | 2022-08-04 | 2024-04-05 | 北京大学人民医院 | 钙离子通道阻滞剂阿折地平在制备治疗子宫内膜癌的药物中的应用 |
CN115778957B (zh) * | 2022-11-04 | 2024-06-21 | 天津中医药大学 | 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用 |
CN116570579A (zh) * | 2023-06-13 | 2023-08-11 | 深圳市泛谷药业股份有限公司 | 一种含有阿戈美拉汀和氟伏沙明的药物组合物及其应用 |
CN118059099B (zh) * | 2024-04-19 | 2024-06-14 | 四川大学华西医院 | 帕罗西汀联合asct2抑制剂用于制备治疗肝癌的药物中的应用及药物组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569624A (zh) * | 2008-04-29 | 2009-11-04 | 石药集团中奇制药技术(石家庄)有限公司 | 氨氯地平在制备治疗细胞增生性疾病药物中的用途 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0721335B1 (en) * | 1993-10-01 | 2005-08-31 | Roche Palo Alto LLC | Mycophenolate mofetil high dose oral suspensions |
CA2207333C (en) * | 1994-12-28 | 2006-10-17 | Janssen Pharmaceutica, Naamloze Vennootschap | Use of nebivolol as an anti-atherogenic |
US6596756B1 (en) * | 1998-09-15 | 2003-07-22 | Eli Lilly And Company | Treatment of fibromyalgia |
US6927223B1 (en) * | 2000-05-26 | 2005-08-09 | Washington State University Research Foundation | Use of serotonin agents for adjunct therapy in the treatment of cancer |
CZ303702B6 (cs) * | 2000-07-07 | 2013-03-20 | Trustees Of Tufts College | Minocyklinové slouceniny |
IL139975A0 (en) * | 2000-11-29 | 2002-02-10 | Univ Ramot | Anti proliferative drugs |
US20040072824A1 (en) * | 2001-06-01 | 2004-04-15 | Adam Telerman | Methods and compositions for the treatment of cancer |
GB0202337D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Birmingham | Cancer treatment |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
MXPA06003066A (es) * | 2003-09-18 | 2006-06-20 | Combinatorx Inc | Combinaciones de farmacos para el tratamiento de neoplasmas. |
BRPI0416275A (pt) * | 2003-11-06 | 2007-01-23 | Celgene Corp | métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada |
EP1753425A4 (en) * | 2004-05-12 | 2009-08-05 | Biorunx Co Ltd | THERAPEUTIC AGENT COMPRISING A NICOTINIC ACID OR DERIVATIVES AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF CANCER |
PL1753713T3 (pl) * | 2004-05-21 | 2017-02-28 | President And Fellows Of Harvard College | Synteza tetracyklin oraz ich analogów |
CN1279980C (zh) * | 2004-10-14 | 2006-10-18 | 孔庆忠 | 一种抗实体肿瘤药物组合物 |
JP2006298781A (ja) * | 2005-04-15 | 2006-11-02 | Geno Membrane:Kk | エストロン3硫酸トランスポーター活性阻害剤 |
TW200716141A (en) * | 2005-05-05 | 2007-05-01 | Combinatorx Inc | Compositions and methods for treatment for neoplasms |
CN101223149A (zh) * | 2005-07-05 | 2008-07-16 | 特瓦制药工业有限公司 | 制备缬沙坦的方法 |
SI1909778T1 (en) * | 2005-07-28 | 2018-07-31 | Academisch Ziekenhuis bij de Universiteit van Amsetrdam | MONOFENOLNE, BENZENDIOLE OR SULFHYDRYAL COMPOUNDS FOR THE USE IN THE TREATMENT OF MELANOMS |
US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
WO2007112280A1 (en) * | 2006-03-23 | 2007-10-04 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
CN101099724A (zh) * | 2006-07-07 | 2008-01-09 | 上海复旦复华药业有限公司 | 一种微粉化来曲唑及其组合物 |
CN101103976A (zh) * | 2006-07-14 | 2008-01-16 | 海南盛科生命科学研究院 | 一种含阿那曲唑的口服药物组合物及其制备工艺 |
EP2114399A2 (en) * | 2007-01-05 | 2009-11-11 | Cornerstone Therapeutics Inc. | R-zileuton for use in conditions associated with increased 5-lipoxygenase and/or leukotriene activity (eg asthma) |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
AU2008269181B2 (en) * | 2007-06-21 | 2014-04-17 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
US20090054312A1 (en) * | 2007-08-22 | 2009-02-26 | Wolf Dieter A | SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases |
US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
CN100563645C (zh) * | 2007-12-06 | 2009-12-02 | 济南帅华医药科技有限公司 | 一种治疗实体肿瘤的蓓萨罗丁缓释植入剂 |
US20090270397A1 (en) * | 2008-04-08 | 2009-10-29 | Orlow Seth J | Methods and compositions for the treatment of cancers, such as melanomas and gliomas |
EP2123626A1 (en) * | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
WO2009147169A1 (en) * | 2008-06-03 | 2009-12-10 | Universite Paris Diderot-Paris 7 | Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia |
CN101612400A (zh) * | 2009-07-22 | 2009-12-30 | 陈志龙 | 血管紧张素ⅱ的1型受体拮抗剂在抗肿瘤中的应用 |
CN101690816A (zh) * | 2009-08-16 | 2010-04-07 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
CN101991553B (zh) * | 2009-08-21 | 2015-02-25 | 北京以岭生物工程技术有限公司 | 一种依西美坦片及其制备方法 |
CN101863806B (zh) * | 2010-03-18 | 2013-02-13 | 湖北省医药工业研究院有限公司 | 抗前列腺癌药物(r)-比卡鲁胺的制备方法 |
US9012511B2 (en) * | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
WO2012015023A1 (ja) * | 2010-07-29 | 2012-02-02 | 国立大学法人京都大学 | 抗がん剤のスクリーニング方法 |
CN103429235A (zh) * | 2010-12-15 | 2013-12-04 | 赖鸿政 | 用于治疗癌症的化合物及其应用 |
CN102631354B (zh) * | 2011-02-11 | 2015-01-21 | 广东泰禾医药科技有限公司 | 含维生素d3和二甲双胍的药物组合物 |
CN102688493B (zh) * | 2011-03-25 | 2014-09-10 | 鼎泓国际投资(香港)有限公司 | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 |
CN102813643B (zh) * | 2011-06-10 | 2014-09-24 | 北京蛋白质组研究中心 | bumetanide在抑制肝癌细胞转移中的应用 |
US9757424B2 (en) * | 2011-09-27 | 2017-09-12 | Biomed Valley Discoveries, Inc. | Compositions and methods of treating gliomas |
WO2013071262A1 (en) * | 2011-11-10 | 2013-05-16 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
CN102600077B (zh) * | 2012-03-29 | 2013-06-05 | 江苏豪森药业股份有限公司 | 吉西他滨或其盐纳米乳剂注射液及其制备方法 |
ES2384069B1 (es) * | 2012-03-29 | 2013-07-04 | Hospital Sant Joan De Déu | Cinacalcet y tumores neuroblásticos |
CN103536607A (zh) * | 2012-07-10 | 2014-01-29 | 邵金辉 | 土霉素,普罗帕酮和安乃近的抗肿瘤作用 |
WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
WO2014036654A1 (en) * | 2012-09-06 | 2014-03-13 | Mcmaster University | Compounds and methods for selectively targeting cancer stem cells |
PT2897620T (pt) * | 2012-09-21 | 2020-09-03 | Intensity Therapeutics Inc | Método de tratamento de cancro |
NZ706420A (en) * | 2012-10-04 | 2018-08-31 | Ab Science | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
CN102872066B (zh) * | 2012-10-19 | 2014-07-02 | 厦门大学 | 伊维菌素及其衍生物的用途 |
CN105142631A (zh) * | 2013-01-14 | 2015-12-09 | 健康诊所有限公司 | 抗癌药物和用途 |
CN103933569B (zh) * | 2013-01-22 | 2017-01-11 | 复旦大学 | 一种抗肺癌药物组合物及其应用、药盒和包装件 |
JP6511430B2 (ja) * | 2013-03-11 | 2019-05-15 | ザ・ブロード・インスティテュート・インコーポレイテッド | がんの治療のための化合物および組成物 |
US20140271727A1 (en) * | 2013-03-18 | 2014-09-18 | National Yang-Ming University | Method of using an antidepressant for increasing immunity of a subject and treating cancer |
CN104161759B (zh) * | 2013-05-16 | 2019-10-08 | 中国科学院上海药物研究所 | 阿那格雷及其衍生物的抗肿瘤用途 |
CN103396419A (zh) * | 2013-08-13 | 2013-11-20 | 海宁市绿升医药科技有限公司 | 肿瘤光动力治疗药二氢卟吩e6-15-乙酯及其制备方法 |
CN103536925B (zh) * | 2013-10-28 | 2015-07-01 | 中国医学科学院基础医学研究所 | 强心苷化合物在非小细胞肺癌治疗中的应用 |
CN103622975B (zh) * | 2013-11-07 | 2016-06-15 | 广东药学院 | 格列吡嗪在制备治疗肿瘤药物中的应用 |
KR20160143775A (ko) * | 2014-04-08 | 2016-12-14 | 더 메서디스트 하스피틀 | iNOS-억제 조성물들 및 이들의 유방암 치료제로서의 용도 |
WO2016062269A1 (zh) * | 2014-10-24 | 2016-04-28 | 朗齐生物医学股份有限公司 | 阿那格雷在用于制备治疗癌症的医药组合物中的用途 |
-
2015
- 2015-10-23 WO PCT/CN2015/092666 patent/WO2016062269A1/zh active Application Filing
- 2015-10-23 TW TW104134928A patent/TW201615197A/zh unknown
- 2015-10-23 TW TW104134933A patent/TWI652060B/zh active
- 2015-10-23 EP EP15852781.2A patent/EP3222278B1/en active Active
- 2015-10-23 WO PCT/CN2015/092761 patent/WO2016062279A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092686 patent/WO2016062271A1/zh active Application Filing
- 2015-10-23 TW TW104134966A patent/TW201615194A/zh unknown
- 2015-10-23 WO PCT/CN2015/092677 patent/WO2016062270A1/zh active Application Filing
- 2015-10-23 CN CN201580057615.0A patent/CN107106523A/zh active Pending
- 2015-10-23 WO PCT/CN2015/092632 patent/WO2016062266A1/zh active Application Filing
- 2015-10-23 TW TW104134956A patent/TW201615196A/zh unknown
- 2015-10-23 US US15/521,540 patent/US10098852B2/en active Active
- 2015-10-23 WO PCT/CN2015/092617 patent/WO2016062265A1/zh active Application Filing
- 2015-10-23 KR KR1020177011094A patent/KR102490334B1/ko active IP Right Grant
- 2015-10-23 TW TW104134942A patent/TW201615195A/zh unknown
- 2015-10-23 TW TW104134961A patent/TW201615193A/zh unknown
- 2015-10-23 TW TW104134954A patent/TW201615222A/zh unknown
- 2015-10-23 WO PCT/CN2015/092776 patent/WO2016062286A1/zh active Application Filing
- 2015-10-23 AU AU2015335391A patent/AU2015335391B2/en active Active
- 2015-10-23 WO PCT/CN2015/092714 patent/WO2016062275A1/zh active Application Filing
- 2015-10-23 TW TW104134940A patent/TW201615186A/zh unknown
- 2015-10-23 AU AU2015335375A patent/AU2015335375B2/en active Active
- 2015-10-23 WO PCT/CN2015/092781 patent/WO2016062290A1/zh active Application Filing
- 2015-10-23 TW TW104134944A patent/TW201615219A/zh unknown
- 2015-10-23 US US15/521,504 patent/US20170304228A1/en not_active Abandoned
- 2015-10-23 TW TW104134908A patent/TWI672150B/zh not_active IP Right Cessation
- 2015-10-23 WO PCT/CN2015/092768 patent/WO2016062281A1/zh active Application Filing
- 2015-10-23 CN CN201580057095.3A patent/CN106999470A/zh active Pending
- 2015-10-23 WO PCT/CN2015/092779 patent/WO2016062288A1/zh active Application Filing
- 2015-10-23 TW TW104134945A patent/TW201615188A/zh unknown
- 2015-10-23 WO PCT/CN2015/092771 patent/WO2016062283A1/zh active Application Filing
- 2015-10-23 TW TW104134959A patent/TW201615223A/zh unknown
- 2015-10-23 TW TW104134950A patent/TWI663969B/zh active
- 2015-10-23 TW TW104134965A patent/TW201615226A/zh unknown
- 2015-10-23 TW TW104134952A patent/TW201615221A/zh unknown
- 2015-10-23 WO PCT/CN2015/092753 patent/WO2016062278A1/zh active Application Filing
- 2015-10-23 TW TW104134963A patent/TW201615224A/zh unknown
- 2015-10-23 WO PCT/CN2015/092782 patent/WO2016062291A1/zh active Application Filing
- 2015-10-23 ES ES15852781T patent/ES2954860T3/es active Active
- 2015-10-23 WO PCT/CN2015/092777 patent/WO2016062287A1/zh active Application Filing
- 2015-10-23 TW TW104134936A patent/TWI621434B/zh active
- 2015-10-23 US US15/521,524 patent/US20170304286A1/en not_active Abandoned
- 2015-10-23 ES ES15852557T patent/ES2973279T3/es active Active
- 2015-10-23 TW TW104134960A patent/TW201615191A/zh unknown
- 2015-10-23 TW TW104134946A patent/TWI663984B/zh active
- 2015-10-23 EP EP15851742.5A patent/EP3235497A4/en not_active Withdrawn
- 2015-10-23 WO PCT/CN2015/092775 patent/WO2016062285A1/zh active Application Filing
- 2015-10-23 TW TW104134924A patent/TW201615218A/zh unknown
- 2015-10-23 WO PCT/CN2015/092746 patent/WO2016062277A1/zh active Application Filing
- 2015-10-23 EP EP15852557.6A patent/EP3210604B1/en active Active
- 2015-10-23 JP JP2017522418A patent/JP6539345B2/ja active Active
- 2015-10-23 WO PCT/CN2015/092702 patent/WO2016062274A1/zh active Application Filing
- 2015-10-23 WO PCT/CN2015/092653 patent/WO2016062267A1/zh active Application Filing
- 2015-10-23 CN CN201580057616.5A patent/CN107106550A/zh active Pending
- 2015-10-23 US US15/521,536 patent/US20170304388A1/en not_active Abandoned
- 2015-10-23 TW TW104134964A patent/TW201615225A/zh unknown
- 2015-10-23 WO PCT/CN2015/092697 patent/WO2016062272A1/zh active Application Filing
- 2015-10-23 US US15/521,517 patent/US10105357B2/en active Active
- 2015-10-23 US US15/521,500 patent/US20170312260A1/en not_active Abandoned
- 2015-10-23 WO PCT/CN2015/092780 patent/WO2016062289A1/zh active Application Filing
-
2017
- 2017-04-20 US US15/492,859 patent/US10045962B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569624A (zh) * | 2008-04-29 | 2009-11-04 | 石药集团中奇制药技术(石家庄)有限公司 | 氨氯地平在制备治疗细胞增生性疾病药物中的用途 |
Non-Patent Citations (1)
Title |
---|
HUANG, WENJING ET AL.: "Effect of Amlodipine on Cell Cycle and Cyclin Expression of Human Breast Cancer MCF-7 Cells and Regulation Mechanism of The Effect", CHINESE JOURNAL OF BIOLOGICALS, vol. 23, no. 03, 31 March 2010 (2010-03-31), pages 290 - 293 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019204764A1 (en) * | 2018-04-19 | 2019-10-24 | Washington University | Compositions and methods of use thereof for treatment of proteinopathies |
US20210228591A1 (en) * | 2018-04-19 | 2021-07-29 | Washington University | Compositions and methods of use thereof for treatment of proteinopathies |
US11931366B2 (en) * | 2018-04-19 | 2024-03-19 | Washington University | Compositions and methods of use thereof for treatment of proteinopathies |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016062266A1 (zh) | 氨氯地平在制备抑制癌症的医药组合物中的用途 | |
CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
RU2784869C1 (ru) | Чиаураниб для лечения мелкоклеточного рака легкого | |
CN112386641A (zh) | 一种用于治疗肺结核的中药组合物及其制备方法和中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15852983 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15852983 Country of ref document: EP Kind code of ref document: A1 |